Kum 2-18 inkar tan Covaxin pawmsak

Subject Expert Committee (SEC) chuan naupang kum 2-18 inkarte tan Bharat Biotech siam Covid-19 vaccine, Covaxin chu emergency thila hman a remtih sak.

Hyderabad-a hmunpui nei, Bharat Biotech chuan an vaccine siam hi September thla khan kum 18 hnuai lam tan trial phase -2 leh phase-3 a zo tawh a, tun thla tir lam khan trial data chu Drugs and Comptroller General of India (DCGI) hnenah a thehlut tawh a ni.

Subject expert panel chuan nimin khan thuchhuah siamin, " Data-te hi uluk taka zirchian a nih hnuah, committee chuan he vaccine hi kum 2-18 inkar tan emergeny thilah hman turin a rawt ta a ni," a ti. Naupangte pual Covaxin siam hi dose hnih tur a ni a, dose khatna leh dose hnihna inkarah ni 20 a tla tur a ni.

Bharat Biotech chuan Covaxin chu khawvel huap pawhin kum 2-18 inkarte tana Covid-19 vaccine pawm hmasak zingah a tel tih sawiin; DGCI, Subject Expert Committee leh Central Drugs Standard Control Organisation (CDSCO) hnenah lawmthu a sawi. Zawrhchhuah thuai a nih theihna turin CDSCO pawmpuina hi an la nghak tih a sawi.

Covaxin hi India rama naupangte hman tura vaccine pawm pahnihna a ni a, August thla khan Zydus Cadila vaccine chu puitling leh kum 12 chung lam hman tura pawm a lo ni tawh a ni.

Serum Institute chuan naupangte hman tur vaccine, Novavax a siam mek bawk a, DGCI chuan thla hmasa khan kum 7-11 inkarte tan clinical trial neih a lo phalsak tawh a, hei bakah hian Biological E siam Corbevax pawh kum nga chunglamah trial neih phalsak a ni tawh bawk.